ASRT241018C1000
- 0.41
- 0.000.00%
Assertio Newsroom
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Assertio Therapeutics: Strong Buy Rating on Robust Portfolio and Strategic Growth
Assertio Holdings Analyst Ratings
Maxim Group Initiates Assertio(ASRT.US) With Buy Rating, Announces Target Price $3
H.C. Wainwright Starts Assertio at Buy, Calls Stock Underrated, Overlooked
Assertio Holdings Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Assertio Therapeutics (ASRT), SurModics (SRDX)
Assertio Holdings Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)
Assertio Holdings Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Henry Schein (HSIC) and Assertio Therapeutics (ASRT)
BWS Financial Maintains Buy on Assertio Holdings, Lowers Price Target to $4
Assertio Holdings Analyst Ratings
Assertio Therapeutics Earns Buy Rating Amid Strategic Acquisitions and Anticipated Rolvedon Revenue Growth
Assertio Holdings Analyst Ratings
BWS Financial Keeps Their Buy Rating on Assertio Therapeutics (ASRT)
Lake Street Sticks to Their Buy Rating for Assertio Therapeutics (ASRT)
Analysts Are Bullish on Top Healthcare Stocks: Panbela Therapeutics (PBLA), Assertio Therapeutics (ASRT)
BWS Financial Adjusts Assertio Therapeutics' Price Target to $10 From $8, Keeps Buy Rating
Lake Street Maintains Buy on Assertio Holdings, Raises Price Target to $9